Pharmaceuticals

SHERIDAN, WYOMING – July 21, 2025 – Novartis is intensifying its strategic push to relocate key drug manufacturing operations to the United States, aiming to safeguard its U.S. market position against potential tariff impacts. In its second-quarter earnings call last Thursday, CEO Vas Narasimhan emphasized the urgency of reshoring production, while acknowledging the complexity of fully transitioning manufacturing operations.

Novartis Targets Full U.S. Production for Key Medicines

Novartis confirmed its commitment to moving the production of its major medicines for the American market entirely to the U.S. “We’re moving as fast as possible to ensure that within the next few years we’re able to produce our key medicines [in the U.S.] and therefore fully mitigate the tariff impact,” stated Narasimhan.

SHERIDAN, WYOMING – July 12, 2025 – Moderna has received full approval from the U.S. Food and Drug Administration for its COVID-19 vaccine, Spikevax, for children aged 6 months through 11 years who are at higher risk of contracting the disease, reinforcing the company’s position as a key innovator in the mRNA vaccine space.

Spikevax, which had previously been available to children only under an emergency use authorization, is now fully approved for:

• Children 6 months through 11 years at increased risk
• Individuals aged 6 months through 64 years at increased risk
• All adults 65 years and older

Moderna expects to make the updated Spikevax shot available ahead of the 2025-2026 respiratory virus season.

Momentum Across Moderna’s mRNA Vaccine Pipeline

SHERIDAN, WYOMING – July 12, 2025 – A landmark release of 200 complete response letters (CRLs) by the U.S. Food and Drug Administration (FDA) has unveiled a decade of regulatory decisions behind once-rejected therapies, now approved and on the market. Among the most revealing cases are Eli Lilly’s Alzheimer’s treatment Kisunla, Sarepta’s Duchenne muscular dystrophy drug Vyondys 53, and Gilead’s long-acting HIV therapy Sunlenca.

This unprecedented act of “radical transparency” by the FDA marks a rare window into the regulatory reasoning typically hidden from public view. Each letter provides detailed insight into the challenges biopharmaceutical companies face—from inadequate safety data to packaging compatibility issues—offering strategic guidance for future drug development and market approval.

Kisunla CRL Highlights FDA’s Long-Term Safety Expectations

SHERIDAN, WYOMING – July 8, 2025 – A coalition of major U.S. medical societies has filed a federal lawsuit against Health and Human Services Secretary Robert F. Kennedy Jr., challenging his directive to remove COVID-19 vaccines from routine immunization schedules for healthy children and pregnant women.

The lawsuit, filed Monday in the U.S. District Court for Massachusetts, responds to Kennedy’s May announcement eliminating these groups from federal COVID-19 vaccine guidelines. The plaintiffs—among them the American Academy of Pediatrics, the American College of Physicians, and the Infectious Diseases Society of America—are seeking immediate legal intervention to reverse the decision.

Medical organizations cite danger to vulnerable populations

SHERIDAN, WYOMING – July 8, 2025 – The newly signed One Big Beautiful Bill from President Donald Trump is poised to reshape the U.S. pharmaceutical policy landscape, restoring expanded orphan drug exemptions from the Inflation Reduction Act (IRA) while introducing significant Medicaid cuts and dropping regulatory reforms on pharmacy benefit managers (PBMs). The bill signals a strategic shift that may benefit the biopharma sector, while raising concerns about access and affordability in public healthcare.

Expanded orphan drug exemptions bolster rare disease R&D

Among the most consequential elements for the pharmaceutical industry is the reinstatement of broader protections for orphan drugs from Medicare price negotiations. The IRA had previously limited exemptions to drugs with only a single rare disease indication, but under the new law, those protections will now extend across multiple indications.

SHERIDAN, WYOMING – July 8, 2025 – BrainStorm Cell Therapeutics is once again at the center of the amyotrophic lateral sclerosis (ALS) treatment debate as patients formally petition the FDA to reconsider the approval of its investigational stem cell therapy, NurOwn. Citing new survival data and expanded access outcomes, the Citizens’ Petition seeks regulatory reassessment of the once-rejected therapy, underscoring the shifting landscape of ALS drug development and patient advocacy.

Renewed Push for Regulatory Reevaluation

The Citizens’ Petition, submitted last week by several individuals living with ALS, requests that the agency approve the stem cell therapy based on “new evidence and totality of evidence.”

SHERIDAN, WYOMING – July 8, 2025 – Regeneron has received accelerated approval from the U.S. Food and Drug Administration (FDA) for its bispecific antibody linvoseltamab, now branded as Lynozyfic, for the treatment of patients with relapsed or refractory multiple myeloma—unlocking a market potential estimated at $600 million.

While the therapy enters a space already led by Johnson & Johnson’s Tecvayli, approved in 2022, Regeneron is seeking to distinguish Lynozyfic through its efficacy profile and flexible dosing advantages. According to analysts at BMO Capital Markets, the approval is a “small win” for Regeneron, noting that Lynozyfic will be a “minor contributor to the company’s broader product portfolio.” The firm estimates around $600 million in potential revenues from the drug.

SHERIDAN, WYOMING – July 8, 2025 – In a landmark agreement that underscores the growing convergence of artificial intelligence and drug discovery, Tokyo-based Chugai Pharmaceutical has entered into a multi-phase research collaboration with Singapore-headquartered biotech Gero to target age-related diseases using AI-driven insights. The deal could exceed $1 billion in total value, positioning both companies at the forefront of longevity-focused pharmaceutical innovation.

AI-Powered Discovery for High-Impact Biologics

Chugai, majority-owned by Roche, will leverage Gero’s proprietary AI target discovery platform to identify novel biological targets linked to aging-related conditions. Based on these targets, Chugai will engineer antibody-based drug candidates using its advanced internal capabilities.

SHERIDAN, WYOMING – July 8, 2025 – Cogent Biosciences is accelerating its strategic trajectory with plans to submit its first New Drug Application (NDA) to the FDA by year-end, following strong Phase II data for its investigational tyrosine kinase inhibitor, bezuclastinib. The move positions Cogent as a serious contender in the systemic mastocytosis treatment landscape, directly challenging Blueprint Medicines' market presence.

Strategic Differentiation in a Competitive Field

SHERIDAN, WYOMING – July 8, 2025 – KalVista Pharmaceuticals has received U.S. FDA approval for its oral treatment Ekterly (sebetralstat), marking a major milestone as the first and only on-demand tablet therapy for hereditary angioedema (HAE) in patients aged 12 and older.

The company confirmed that the drug will be available in the U.S. “immediately” under the brand name Ekterly. According to KalVista’s press release, it is “the first and so far only oral and on-demand treatment for hereditary angioedema (HAE).”

Regulatory delays and internal agency tensions

Ekterly’s road to approval was not smooth. Last month, the FDA informed KalVista that it would not meet its original target action date of June 17, citing “heavy workload and limited resources,” according to the biotech’s announcement at the time.